In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for MOTS c Peptides for Research 99% Purity Certified FDA to weigh easing limits on unproven peptides favored by RFK Jr. and other MAHA figures Pittsburgh Post Gazette Peptide BPC 157 for Injury Repair Peptides Lack Reliable Safety Information, Watchdog Warns